Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $37.3333.

A number of equities analysts have recently weighed in on the company. Leerink Partners upped their price objective on Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research note on Friday, July 17th. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Monday, May 18th. Finally, UBS Group boosted their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st.

Nanobiotix Price Performance

NASDAQ:NBTX opened at $38.38 on Friday. The business’s 50-day simple moving average is $37.83 and its two-hundred day simple moving average is $33.39. Nanobiotix has a 52 week low of $6.09 and a 52 week high of $57.14.

Institutional Investors Weigh In On Nanobiotix

Several institutional investors and hedge funds have recently modified their holdings of NBTX. Royal Bank of Canada lifted its holdings in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after buying an additional 2,500 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Nanobiotix during the fourth quarter worth $220,000. Finally, Millennium Management LLC purchased a new position in Nanobiotix during the fourth quarter valued at $390,000. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.